Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Acutus Medical sale of its left-heart access portfolio products
We are advising Acutus Medical on the transaction
Ingenovis Health acquisition of VISTA Staffing Solutions
We are advising Ingenovis Health, Cornell Capital and Trilantic on the transaction
Natus Medical $1.2 billion acquisition by ArchiMed
We are advising Natus Medical on the transaction
Charles River Laboratories $295 million acquisition of Explora BioLabs Holdings
We advised Charles River on the transaction
Novo Nordisk insulin pricing litigation victory
We prevailed in having the complaint dismissed with prejudice
Owens & Minor $600 million notes offering
The high-yield notes are due 2030
AN2 Therapeutics $69 million IPO
The shares are listed on the Nasdaq Global Select Market
Roche Holdings $5 billion notes offering
We advised Roche on the Rule 144A / Regulation S offering comprising five tranches of notes
Denali $400 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
$12.6 billion financing for investor group acquisition of a software company
We advised the debt and preferred equity financing sources on the transaction